Author's response to reviews

Title: Safety and efficacy of vemurafenib in end stage renal failure

Authors:

Mahesh Iddawela (mahesh.iddawela@unimelb.edu.au)
Sarah Crook (sarahcook@gmail.com)
Leah George (leahcge@hotmail.com)
Amit Lakkaraju (amitlakkaraju@gmail.com)
Nihal Nanayakkara (nihal.nana@gvhealth.org.au)
Roland Hunt (Roland.Hunt@gvhealth.org.au)
William R Adam (wadam@unimelb.edu.au)

Version: 3
Date: 26 November 2013

Author's response to reviews: see over
Title: -Please note that email addresses should be provided for all authors.

Abstract:

common toxicity criteria (CTC) grade 3 changed from common toxicity criteria grade 4.

Background:

-Sydney, Australia added to Roche Pharmaceuticals.

-Units for LDH added- U/L.

-ECG expanded to electrocardiograms

-"There was other significant medical history" changed to "There was no other significant medical history of relevance".

-"In addition, it was noted that the patient had also had a high QTc interval (512 msec) 2 years previously, which resolved spontaneously, and there were no other documented episodes of a prolonged QTc interval" changed to "In addition, it was noted that the patient had also had a high QTc interval (512 msec) 2 years previously, which resolved spontaneously and no precipitating cause was found, and there were no other documented episodes of a prolonged QTc interval".

-"An additional ECG confirmed that the QTc interval was again normal and the fluctuations were not associated with any symptoms" changed to "An additional ECG a week later confirmed that the QTc interval was normal and the fluctuation was not associated with any symptoms".

Discussion heading deleted.